Good day, ladies and gentlemen, and welcome to the Dynavax Technologies fourth quarter and full year 2024 financial results ...

Q4 2024 Earnings Call Transcript February 20, 2025 Dynavax Technologies Corporation reports earnings inline with expectations ...

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 25% and 0.46%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (NASDAQ:DVAX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by William Blair in a note issued to investors on Friday,RTT News reports. William Blair also issued ...

Dynavax Technologies Corporation ( NASDAQ: DVAX) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - ...

Learn about Deep Track Capital's proxy fight with Dynavax (DVAX) and their push to prioritize Heplisav's growth.

The Emeryville, California-based company said it had net income of 5 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

HEPLISAV-B® 2024 net product revenue grew 26% year-over-year to $268 million; net product revenue expected to be $305 to $325 million in 2025 Top-line results in ...

During the last three months, 4 analysts shared their evaluations of Dynavax Technologies DVAX, revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...